The Financial Express4h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
pharmaphorum17h
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
devdiscourse9h
US Health Sector's Strategic Moves and Legislative Impacts Unfold
The health sector is witnessing crucial developments including US turkey flu testing advocacy, WHO lobbying to retain US membership, and Medicare price negotiations involving major drugs. Meanwhile, ...
Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
FTSE 100 hits all-time high in 2025 – should you invest?
The FTSE 100 hit an all time high this week, and could reach 9,000 points by the end of 2025 according to the investment ...
Prediction: this FTSE 250 trust will beat Rolls-Royce shares over the next 5 years
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...